Menu Search
Equities

Lattice Biologics Ltd

LBL.H:NEX

Lattice Biologics Ltd

Actions
  • Price (CAD)0.04
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Jun 03 2021.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Lattice Biologics Ltd had net income fall 46.52% from a loss of 1.01m to a larger loss of 1.48m despite a 12.60% increase in revenues from 2.19m to 2.46m.
Gross margin28.53%
Net profit margin-61.08%
Operating margin-30.96%
Return on assets-61.69%
Return on equity--
Return on investment--
More ▼

Cash flow in USDView more

In 2020, Lattice Biologics Ltd increased its cash reserves by 265.16%, or 41.55k. The company earned 536.15k from its operations for a Cash Flow Margin of 21.76%. In addition the company generated 97.48k cash from financing while 592.08k was spent on investing.
Cash flow per share-0.0067
Price/Cash flow per share--
Book value per share0.0011
Tangible book value per share-0.0055
More ▼

Balance sheet in USDView more

Lattice Biologics Ltd uses little or no debt in its capital structure.
Current ratio0.00
Quick ratio0.00
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.